Source: Pharamceutical Technology

AVEO: AVEO Pharmaceuticals gets grant for decreasing blood urea nitrogen levels in hyperuricemia using anti-gdf15 antibody

Discover a groundbreaking method to treat renal disorders with AVEO Pharmaceuticals Inc's patented anti-GDF15 antibody. Learn how this innovative approach targets hyperuricemia and CKD for improved renal function.

Read full article »
AVEO's Competitors | AVEO's News | AVEO's Financials
Stay up-to-date with the latest news on AVEO
Est. Annual Revenue
$25-100M
Est. Employees
100-250
Michael P. Bailey's photo - President & CEO of AVEO

President & CEO

Michael P. Bailey

CEO Approval Rating

83/100

Read more
Stay up-to-date with the latest news on AVEO